Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zentek ( (TSE:ZEN) ) has provided an update.
Triera Biosciences, a Zentek subsidiary, is launching contract research organization services that combine custom aptamer discovery, biosensor engineering, and optional machine-learning classification for pharmaceutical, biotechnology, and diagnostics companies. Built on an exclusive 20-year worldwide license from McMaster University for aptamer applications, the platform offers a differentiated alternative to antibody-based tools and includes a growing catalogue of high-affinity aptamers for targets such as influenza A, SARS-CoV-2, VEGF, syphilis, norovirus, and C. difficile.
The new offering follows an asset-light model where client-funded projects deliver validated aptamer and biosensor-ready assets while Triera retains the underlying intellectual property, aligning with Zentek’s broader IP-commercialization strategy. Management expects these CRO activities to create earlier and more predictable revenue streams, strengthen Zentek’s position in high-growth diagnostic markets, and potentially lead to follow-on development, licensing deals, and product partnerships across major infectious disease and oncology detection segments.
The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$0.75 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.
Spark’s Take on ZEN Stock
According to Spark, TipRanks’ AI Analyst, ZEN is a Neutral.
The score is primarily held back by weak financial performance—limited revenue scale, negative margins, and continued cash burn—only partially offset by a low-leverage balance sheet. Technicals add pressure as the stock trades below key moving averages with a negative MACD, while valuation signals are inconclusive due to negative earnings and no dividend data.
To see Spark’s full report on ZEN stock, click here.
More about Zentek
Zentek Ltd. operates in advanced materials and life sciences, with its wholly owned subsidiary Triera Biosciences focused on aptamer-based molecular recognition technologies for diagnostics and therapeutics. Triera targets pharmaceutical, biotechnology, and diagnostics clients in Canada, the United States, Europe, and other markets that require high-performance detection tools for infectious diseases and oncology.
Average Trading Volume: 65,656
Technical Sentiment Signal: Sell
Current Market Cap: C$83.88M
For an in-depth examination of ZEN stock, go to TipRanks’ Overview page.